Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Theresa L Chang · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · 2024 · $235,500 — PROJECT SUMMARY Coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been a major challenge for public health since the first case was reported in December 2019. In May 2023, the WHO and CDC marked the end of the COVID-19 public health emerg…
Anthony Bowen · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2024 · $193,644 — PROJECT SUMMARY / ABSTRACT: Rationale: Continued evolution of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has led to immune-evasive variants that pose a persistent threat to global public health. Updated vaccines are needed to provide improved immune responses against emerging varia…
Erwin London · STATE UNIVERSITY NEW YORK STONY BROOK · 2024 · $576,160 — We aim to understand biomembrane structure/function with the aid of a lab-achieved breakthrough in control of membrane phospholipid and sphingolipid composition via cyclodextrin-catalyzed lipid exchange. Lipid exchange is generally efficient (80-100%), and permits preparation of lipid vesicles mimic…
James B Munro · UNIV OF MASSACHUSETTS MED SCH WORCESTER · 2024 · $502,500 — SUMMARY Influenza A virus (IAV) hemagglutinin (HA) is the canonical example of a class-I viral fusion protein, and thus provides an ideal model system for understanding the fusion mechanisms of many different viruses. Numerous other viral envelope glycoproteins, including the SARS-CoV-2 spike, are b…
MARK ROBERTS LOONEY · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2024 · $623,280 — Project Summary/Abstract The acute respiratory distress syndrome (ARDS) was first formally described in 1967, but it has likely been the predominant cause of death in pandemic viral infections for centuries. Now, the world is at grips with a new pandemic from SARS-CoV-2, or COVID-19, which has infec…
Bing Chen · BOSTON CHILDREN'S HOSPITAL · 2024 · $199,874 — Project Summary Viral fusion proteins are fascinating protein folding machineries capable of adopting completely different conformations during the fusion process; they are also important vaccine and therapeutic targets. Previous studies have revealed both pre- and post-fusion conformations of the s…
Prakash Shrestha · UNIVERSITY OF KENTUCKY · 2024 · $120,258 — Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and its transmission across the world was the cause of the COVID-19 pandemic. The CoV entry is mainly initiated by the binding of furin cleavage activated spike (S) protein with ACE2 receptor protein on the surface of host cell. …
Michael A Barry · MAYO CLINIC ROCHESTER · 2024 · $745,752 — Abstract Most gene-based vaccines are replication-defective mRNA, DNA, or adenovirus (Ad) vaccines. In each case, the vaccine delivers its one copy of an antigen gene and expresses "1X" of the antigens that are encoded by the vaccine. We developed single cycle Ad (SC-Ad) vaccines that replicate vacc…
Paul John Norman · UNIVERSITY OF COLORADO DENVER · 2024 · $706,411 — Summary To ensure a successful and sustained response to the COVID-19 crisis it becomes imperative that the functional implications of the considerable genotypic and phenotypic variation in natural human immunity are understood. Natural killer (NK) cells have major roles in controlling the innate an…
PETER William RAMIREZ · CALIFORNIA STATE UNIVERSITY LONG BEACH · 2024 · $180,599 — Human Immunodeficiency Virus Type 1 (HIV-1) and Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2) are two enveloped RNA viruses that affect significant proportions of the global population. HIV- 1 and SARS-CoV-2 rely on lipid rafts to facilitate viral entry, assembly, and release, bu…
NORMAN R HARRIS · LOUISIANA STATE UNIV HSC SHREVEPORT · 2024 · $365,000 — Approximately 32-44% of the adult US population has hypertension, with one of the many complications being hypertensive retinopathy. In one study, the prevalence of retinopathy was found to be 85% amongst those with severe hypertension, and 25% for those with mild hypertension. Retinal consequences …
DAVID BAKER · UNIVERSITY OF WASHINGTON · 2024 · $692,102 — PROJECT SUMMARY One of the most pressing public health priorities for the COVID-19 pandemic is the development of an effective and inexpensive therapeutic. The long-term goal of this proposal is to develop such COVID-19 treatments, as well as the methods needed to rapidly create such molecules as so…
Jorge Alberto Acuna · UNIVERSITY OF PENNSYLVANIA · 2024 · $48,974 — Project Summary/Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic and severely impacted public health. SARS-CoV-2 primarily infects respiratory epithelium cells expressing host factors required for viral entry. Infection is initiated when the SARS-CoV…
MICHAEL DAVID ALPERT · EMMUNE, INC · 2024 · $1,000,000 — We are developing vaccine antigens for SARS-CoV-2 that focus the antibody response onto neutralizing epitopes in the receptor binding domain (RBD) of the viral Spike (S) protein. Booster antigens derived from variants of SARS-CoV-2 would especially benefit from being limited to the RBD, due to the p…
Chitra Upadhyay · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2024 · $858,835 — Project Summary Developing an effective HIV vaccine to curb HIV infections is a global urgency. Env is the sole target for broadly neutralizing antibodies (bNAbs), and is the focus of vaccination strategies. One barrier to a protective HIV vaccine is the dense array of glycans that covers the surfac…
Jack H Freed · CORNELL UNIVERSITY · 2024 · $410,000 — For many years Freed has pioneered the development of electron-spin resonance (ESR) methods for the study of proteins and their dynamical effects on membranes. The goal of this proposal is to use those ESR techniques to advance our knowledge of 1) viral membrane fusion and 2) Intrinsic Disordered Pr…
Thomas Eggerman · CLINICAL CENTER · 2024 — Using human SR-BI (hSR-BI) and human SR-BII (hSR-BII) transgenic mice, we have found that SR-BI and, to a lesser extent, SR-BII protect against bacterial LPS-induced lung damage: At 20 hours after intratracheal LPS instillation, the extent of pulmonary inflammation and vascular leakage was signific…
BARBARA K FELBER · DIVISION OF BASIC SCIENCES - NCI · 2024 · $1,786,891 — The development of a safe and effective vaccine and to improve treatment strategies aiming to reduce/eliminate the virus reservoir are currently at the forefront of our research. Based on our recognition of the fundamental mechanisms of mRNA expression, exemplified by the regulated expression of HIV…
Clifford Lane · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $73,280 — Research in this project is currently focused on six areas. These are: characterization of the survivors of the anthrax attacks of 2001; characterization of emerging respiratory infections including SARS, COVID-19, and influenza; evaluation of experimental vaccines and treatments for Ebola virus; c…
Mario Borgnia · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · 2024 · $727,531 — The goal of this project is to understand the molecular mechanisms involved in the infection of mammalian cells by enveloped viruses. Using cryogenic electron microscopy (cryo-EM) we have established workflows to determine the structure of the molecular machines involved in these processes. We solve…